ClinicalTrials.gg
TerminatedNCT02699853Updated May 3, 2019

Robotic or Open Radical Cystectomy in Treating Patients With Bladder Cancer

An interventional study of Questionnaire Administration and Radical Cystectomy in Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma and Stage II Bladder Urothelial Carcinoma, sponsored by University of Southern California. Terminated at 1 site in United States. Per ClinicalTrials.gov, last updated 2019-05-03.

Sponsored by University of Southern California · Not applicable, Interventional, and Supportive care

Why this study was terminated
PI decided to revamp the protocol completely and will submit as new study.
Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Randomized
Sex
All
01

Study summary

This randomized phase II trial studies how well robotic radical cystectomy (RRC) or open radical cystectomy (ORC) works in treating patients with bladder cancer. Cystectomy is a surgical procedure to remove all or part of the bladder (the organ that holds urine) or to remove a cyst (a sac or capsule in the body). In RRC, the the surgeon makes small cuts in the abdomen and uses a thin, lighted instrument with a camera attached called a scope. With the help of a robot, the surgeon removes the bladder and other nearby structures. In ORC, the surgeon makes a cut into the lower abdomen to expose the urinary tract in order to remove the bladder and nearby structures. It is not yet known whether RRC or ORC has fewer complications, better quality of life, and faster recovery time in treating patients with bladder cancer.

Read the detailed description

PRIMARY OBJECTIVES:

I. To compare RRC to ORC in terms of the difference in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core (QLQC)30 quality of life instrument assessed at baseline to day 30 after radical cystectomy (RC).

II. To compare RRC to ORC in terms of the 90-day high-grade complication rate (where high grade is defined as Clavien-Dindo grade 3-5).

III. To compare the peri-operative cost of the RC procedure, as defined as from the day of hospital admission to the day of hospital discharge.

SECONDARY OBJECTIVES:

I. To estimate the differences between RRC and ORC in terms of the following quality of life outcomes: Narcotic requirements prior to RC, during hospital stay and on days 7, 14, 30, 6 weeks, and 3, 6, 9 and 12 months; Visual Analog Scale (VAS) pain score prior to RC and on days 7, 14, 30, 6 weeks, and 3, 6, 9 and 12 months; the EORTC-QLQ-30 prior to RC and at 3, 6, 9, and 12 months; the bladder cancer index (BCI) at 30 days and 3, 6, 9, and 12 months; the Sexual Health Inventory for Men (SHIM) prior to RC and at 3, 6, 9, and 12 months; the World Health Organization (WHO) Quality of Life (QOL) questionnaire prior to RC and at 30 days and 3, 6, 9, and 12 months.

II. To estimate the differences between RRC and ORC in terms of the following surgical and complication outcomes: all complications occurring intraoperatively, during postoperative hospitalization and during the 90 days post cystectomy assessed at 7, 14, and 30 days; at 6 weeks and at 3 months-graded according to the Clavien-Dindo classification; all complications, all grade 3+ complications, and all grade 4+ complications; time to oral intake; estimated blood loss during surgery, number of transfusions on the day of surgery; drop in hematocrit at 24 hours; lymph node yield; and positive surgical margin.

III. To estimate the differences between RRC and ORC in terms of the following cost-related outcomes: operation room time; number of disposables used; pharmacy costs; length of hospital stay; admission to intensive care unit (ICU) prior to discharge \& length of stay in ICU; number of hospital readmissions within 30 and 90 days (3 months); necessary tests/procedures to treat complications during hospitalization and within 30 and 90 days.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients undergo RRC at day 0.

ARM II: Patients undergo ORC at day 0.

After completion of study treatment, patients are followed up at 7 days, 30 days, 6 weeks, and at 3, 6, 9, and 12 months.

02

Conditions studied

  • Stage 0is Bladder Urothelial Carcinoma
  • Stage I Bladder Urothelial Carcinoma
  • Stage II Bladder Urothelial Carcinoma
  • Stage III Bladder Urothelial Carcinoma
03

In context

Lead sponsor

University of Southern California is the lead sponsor of 789 studies on the registry; 136 are open to participants now.

Of its 69 completed or terminated interventional studies of FDA-regulated products, 32 (46%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Indication for radical cystectomy for urothelial cancer
  • All types of urinary diversions
  • Tis-T3 Urothelial cancer; patients will be stratified according to clinical stage
  • Ability to consent
  • Patient meets criteria to be a surgical candidate

Exclusion criteria

Exclusion Criteria:

  • Inability to give consent or adhere to follow-up schedule
  • T4 tumor
  • Bulky lymphadenopathy (> 2 cm)
  • Prior pelvic radiation
  • Not surgical candidate because of significant co-morbidity
  • Uncontrolled coagulopathy
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Arm I (RRC)

    Patients undergo RRC at day 0.

    Other: Questionnaire Administration · Procedure: Radical Cystectomy

  • Experimental
    Arm II (ORC)

    Patients undergo ORC at day 0.

    Other: Questionnaire Administration · Procedure: Radical Cystectomy

Interventions

  • OtherQuestionnaire Administration

    Ancillary studies

  • ProcedureRadical Cystectomy

    Undergo RRC

    Also known as: Complete Cystectomy

  • ProcedureRadical Cystectomy

    Undergo ORC

    Also known as: Complete Cystectomy

06

What researchers measure

Primary outcomes

  1. Change in patient reported quality of life, as measured by the EORTC-QLQ-C30

    The results for the two arms will be summarized using graphical methods and standard descriptive statistics. Means (or medians) and associated 95% confidence intervals-for each arm separately and for the difference-will be used to display the patterns. For QoL variables that are assessed at multiple times post cystectomy, regression methods that accommodate repeated measures will be used to assess patterns over time. Analyses will compare the two arms using general linear regression models and stratifying for the four variables used for stratification prior to randomization.

    Time frame: Baseline and 1-month post cystectomy

Secondary outcomes

  1. Change in erectile dysfunction, as measured by the SHIM score

    Time frame: up to 12 months

07

Study locations

1 site
  • USC / Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2016 to primary completion in Nov 2018, 31 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2016
First posted
Mar 4, 2016
StartActual
Apr 12, 2016
Primary completionActual
Nov 16, 2018
CompletionActual
Nov 16, 2018
Last update
May 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02699853
Responsible party
Sponsor
First posted
Mar 4, 2016
Start date
Apr 12, 2016
Primary completion
Nov 16, 2018
Completion
Nov 16, 2018
Last update
May 3, 2019

Study contacts

Mihir Desai
principal investigator · University of Southern California

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion